Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

These amendments introduce no new matter and support for such is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter.

Listing of Claims:

Claims 1-19 (canceled).

20. (New) A method of treatment for diabetes, the method comprising administering to a subject in need thereof, a composition comprising P- and A-type inositolphosphoglycans, a P-type inositolphosphoglycan (IPG), or an antagonist of an A-type IPG.

21. (New) The method of claim 20, wherein the composition has a ratio of P-type IPG to A-type IPG of from about 4:1 to about 6:1.

22. (New) The method of claim 21, wherein the ratio is about 6:1 for a male subject or about 4:1 for a female subject.

23. (New) A method of treatment for obese type II diabetes, the method comprising administering to a subject in need thereof, a composition comprising a P-type IPG and/or an A-type IPG antagonist.

24. (New) The method of claim 23, wherein the A-type IPG antagonist is a monoclonal antibody capable of specifically binding an A-type IPG.

25. (New) A method of treatment for IDDM or lean type II diabetes (NIDDM), the method comprising administering to a subject in need thereof, a composition comprising a mixture of a P-type IPG and an A-type IPG.

26. (New) The method of claim 25, wherein the mixture comprises a ratio of P-type IPG to A-type IPG of about 6:1 for a male subject or about 4:1 for a female subject.

27. (New) A pharmaceutical composition comprising a P-type IPG and/or an A-type IPG antagonist and a pharmaceutically acceptable carrier.

28. (New) The pharmaceutical composition of claim 27, wherein the A-type IPG antagonist is a monoclonal antibody capable of specifically binding an A-type IPG.

29. (New) A pharmaceutical composition comprising a mixture of a P-type IPG and an A-type IPG and a pharmaceutically acceptable carrier.

30. (New) The composition of claim 29, wherein the mixture comprises a ratio of P-type IPG to A-type IPG of from about 4:1 to about 6:1.